Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: PCSS who wrote (2084)	4/20/2004 9:54:24 PM
From: tuck	Read Replies (2) \| Respond to of 3044

Just be thankful I don't post abstracts that are as cryptic as some of Rick's or Miljenko's. Those guys often make you work to connect the dots. Which is actually a good exercise. Anyhow, many of the recent abstracts I've posted highlight the potential for additivity - in some cases synergy - with Velcade and a lot of other drugs. Much of this is preclinical, so it doesn't directly effect your investment until someone takes one of these promising combos into trials. It seems to point to a wider market for Velcade, but, of course the real upside is if it works in some solid tumors. This is unclear, but hints should be coming over the next several months and beyond. I seem to remember that hypoxic - oxygen starved - tumors were the most susceptible to Velcade. Not sure how many cancers have that feature. Edit: rather a lot, according to this freebie from Medscape, a CME course featuring none other than Julian Adams, the developer of the drug, doing the teaching. Good stuff! medscape.com Cheers, Tuck